3/5/2014 9:16:34 AM
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that three poster presentations including clinical data on its lead drug candidate, BIND-014 and preclinical data on its AstraZeneca collaboration based on Barasertib (AZD1152), will be presented at the upcoming American Association of Cancer Research (AACR) meeting which takes place April 5-9, 2014 in San Diego, CA.
Help employers find you! Check out all the jobs and post your resume.
comments powered by